BCL2L1 and triple-negative breast carcinoma: On the other hand, the hyperphosphorylation of Brd4 due to the downregulation of the phosphatase PP2A [156] and elevated expression ratio of BCL2L1/BCL-XL [156] has also been reported to contribute to BET inhibitor resistance in triple-negative breast cancer.